In November 2025 the FDA quietly did something that reshaped women’s health care overnight. The agency removed the black box warning from six systemic hormone therapy products. Those warnings, which had labeled every package of HRT for over two decades with dire cardiovascular, breast cancer, and dementia risks, were formally acknowledged to be outdated, misapplied, and in many cases actively wrong for the women most likely to benefit from treatment.
For any woman who was told a decade ago that HRT was too risky to consider, or who watched her doctor hesitate on prescribing it, this changes the conversation. The evidence had actually shifted years ago. What changed in 2025 was that the regulatory language finally caught up.
This guide explains what specifically the FDA changed, what the science actually says in 2026, who should reconsider HRT, and what the practical implications are for women in perimenopause and menopause. For our full page on hormone therapy, see our hormone replacement therapy.
What Exactly Did the FDA Change?
In November 2025 the Department of Health and Human Services and the FDA jointly announced the removal of the boxed warnings from six systemic estrogen and combination hormone therapy products. The warnings had cited elevated risk of cardiovascular events, invasive breast cancer, and probable dementia.
The new labeling does not eliminate the discussion of risks. It relocates and recontextualizes them. Where the black box previously suggested these risks applied to all HRT for all women, the updated labeling reflects the actual evidence: risks vary significantly by age at initiation, formulation used, delivery method, and duration of therapy.
The change is a formal correction of what many menopause specialists had been saying for a decade. The 2002 Women’s Health Initiative findings that produced the original warnings were based on a study population that was on average 63 years old, more than 10 years past menopause, and used a specific oral combination hormone therapy that is not the standard prescribing pattern today. The findings were real for that population. The warnings were then applied to every woman on every form of HRT regardless of age, formulation, or context.
The black box warning was written for a specific study population and a specific formulation from 2002. Applying it to every woman on every form of HRT for two decades was an overcorrection. The 2025 FDA action is the formal acknowledgment of that.
What Does the Actual Evidence Say Now?
Modern menopause research has produced a much more nuanced picture of HRT risk and benefit.
Timing Matters (The Timing Hypothesis)
HRT started within 10 years of menopause onset or before age 60 has a substantially different risk profile than HRT started 15 or 20 years post menopause. The Kronos Early Estrogen Prevention Study and multiple follow up analyses of the original WHI data support this. Starting HRT early carries lower cardiovascular risk and clearer benefit than starting late.
Delivery Method Matters
Transdermal estrogen (patches, gels, sprays) has meaningfully lower risk of blood clots than oral estrogen because it bypasses the liver first pass metabolism. This distinction was not made in the original black box warning. Most modern prescribing favors transdermal delivery when feasible.
Formulation Matters
The WHI used conjugated equine estrogens plus medroxyprogesterone acetate. Modern prescribing often uses estradiol (a bioidentical form) and micronized progesterone, which have somewhat different risk profiles. Combination products, cyclical vs continuous dosing, and duration of therapy all affect the overall picture.
Duration and Individual Risk Factors Matter
Long duration HRT has different considerations than short course HRT. Personal cardiovascular risk, breast cancer family history, clotting history, and other factors all shape the individual decision. HRT is not one size fits all.
Who Should Now Reconsider HRT?
Women who may benefit from reconsidering HRT after the 2025 changes include:
- Women in perimenopause or early menopause who were previously told HRT was too risky
- Women dealing with vasomotor symptoms (hot flashes, night sweats) affecting sleep and quality of life
- Women with vaginal atrophy or genitourinary symptoms affecting intimacy and daily comfort
- Women at increased risk of osteoporosis where HRT can protect bone density
- Women with family history of dementia who want to explore the emerging protective evidence
- Women who had surgical menopause at a younger age and never received appropriate replacement
- Women who tried HRT briefly, encountered adverse reactions to one formulation, and were told no forms would work
The right way to reconsider is not to self prescribe or rush into treatment. It is to have a comprehensive consultation with a provider trained in modern menopause management. Our resource on the complete hormone panel for women covers what to expect from a proper evaluation.
How Does This Change What Providers Should Be Prescribing?
The FDA action reflects what the leading professional societies have been saying for years. The Menopause Society, ACOG, and international menopause organizations have all published position statements supporting HRT for appropriate candidates when initiated within the timing window.
In practice, this means providers who stopped prescribing HRT during the 2002 to 2015 backlash are increasingly returning to it. Providers newly trained in this era encounter HRT as a legitimate first line tool for menopausal symptoms rather than a last resort.
The prescribing pattern that has evolved is not the WHI approach of high dose oral conjugated equine estrogen with synthetic progestogen. It is more often lower dose transdermal estradiol with micronized progesterone, sometimes with vaginal estrogen added for local symptoms, and sometimes with low dose testosterone in appropriate patients. Our resource on bioidentical hormone pellet therapy covers the specific pellet form of bioidentical therapy that we use for many patients.
What Are the Real Risks and How Are They Discussed Now?
HRT still has real risks. Removing the black box did not remove those risks. It removed the misapplication of them. Modern honest discussion of HRT risk includes:
- Small absolute increased breast cancer risk with long term combination therapy (typically discussed as extra cases per 1,000 women per year rather than percent increases)
- Increased blood clot risk with oral estrogen (much less with transdermal)
- Individual cardiovascular risk based on age at initiation and pre existing risk factors
- Endometrial protection: women with a uterus need progesterone alongside estrogen to prevent endometrial cancer
- Gallbladder disease risk slight elevation
- Individual variability in tolerance and side effect profiles
The honest conversation now is: your specific risk depends on your age, your family history, your current health, the specific formulation, and the delivery method. A blanket “HRT is dangerous” statement is no more accurate than a blanket “HRT is safe” statement. Our companion piece on is HRT safe for women in 2026 covers the risk analysis in more depth.
What About the Dementia Prevention Angle?
One of the newest and most discussed HRT research areas is the potential role of estrogen in protecting cognitive function and reducing dementia risk. The research is early but promising. Estrogen has known effects on brain regions involved in memory and cognition. Loss of estrogen at menopause corresponds with changes some women experience in cognitive function.
Emerging data from long term follow up studies suggests women who start HRT during the timing window (within 10 years of menopause) may have modestly reduced dementia risk compared to women who do not. The evidence is not yet definitive enough to recommend HRT specifically for dementia prevention, but it is strong enough that many menopause specialists now discuss it as part of the overall benefit assessment.
For patients specifically interested in the cognitive angle, careful discussion of individual risk and benefit is essential. This is not a case for self initiation of HRT. It is a case for a thorough conversation with an experienced provider. Related symptoms like perimenopause symptoms that come with perimenopause often improve with appropriate HRT even when dementia protection is not the primary goal.
What Should You Do Next?
If you have been on the fence about HRT for years because of the old warnings, the 2026 landscape has meaningfully changed what a reasonable evaluation looks like. Practical next steps:
- Book a comprehensive consultation with a provider trained in current menopause management
- Request appropriate baseline labs including hormone panel, cardiovascular risk markers, and cancer screening review
- Bring your family history including maternal and paternal cancer history, cardiovascular disease, and cognitive decline
- Discuss your specific symptoms and goals, not just “I want HRT”
- Ask about delivery methods (transdermal vs oral vs pellet vs vaginal) and why one might fit your case better than another
- Ask about duration expectations, follow up schedule, and how the plan will be reassessed over time
- If vaginal or urinary symptoms are primary, ask specifically about local vaginal estrogen, which has its own risk profile distinct from systemic HRT. Our vaginal atrophy treatment resource covers this in detail
- For weight, energy, and metabolic concerns alongside hormonal changes, integrated care that addresses both hormone therapy and metabolic optimization tends to produce better outcomes than either alone. Our resource on menopause weight gain covers this crossover
Why This News Matters Beyond the Immediate Change
The FDA action in 2025 is significant beyond the specific label change. It signals a broader recalibration of how women’s health information gets communicated. Warnings written for a specific study population should not be extrapolated to all women. Risk should be discussed in absolute terms not just relative terms. Timing, formulation, delivery method, and individual factors all matter.
For women who lived through the 2002 backlash and either never started HRT or stopped abruptly after the WHI findings, this is an invitation to have the conversation again with a provider working from current evidence rather than 20 year old headlines.
Frequently Asked Questions
Did the FDA really remove the black box warning on HRT?
Yes. In November 2025 the Department of Health and Human Services and the FDA jointly announced the removal of boxed warnings on six systemic hormone therapy products, citing warnings that were originally based on findings that did not apply to modern prescribing patterns.
Is HRT now considered safe for all women?
No. The FDA action does not mean HRT is universally safe. It means the blanket warning language did not accurately reflect modern evidence. Individual risk still depends on age, family history, formulation, delivery method, and personal risk factors. Proper evaluation is still needed.
What is the difference between the old and new HRT approach?
Old approach: high dose oral conjugated equine estrogen plus synthetic progestogen, often started well after menopause. Modern approach: lower dose transdermal estradiol plus micronized progesterone, ideally started within 10 years of menopause, tailored to individual symptoms and risk.
If I stopped HRT years ago because of the warnings, should I restart?
Possibly, but not without proper evaluation. If you are within the timing window (within 10 years of menopause or under age 60) and have symptoms affecting your quality of life, restarting HRT is reasonable to discuss. A comprehensive consultation with a provider trained in modern menopause management is the right first step.
Does HRT prevent dementia?
Emerging research suggests HRT started within the timing window may modestly reduce dementia risk, though the evidence is not yet definitive enough to recommend HRT specifically for dementia prevention. Most providers discuss it as part of the overall benefit assessment rather than as a standalone reason to start.
Is transdermal estrogen safer than oral estrogen?
In terms of blood clot risk, yes. Transdermal estrogen bypasses liver first pass metabolism and has meaningfully lower blood clot risk than oral estrogen. For most women who are candidates for HRT, transdermal delivery is the preferred starting point.
Want to reconsider HRT with a provider trained in modern menopause medicine? Book a consultation with Dr. Verdeza at G-Nouva in Doral, Miami. Call (786) 453-2785 or visit gnouva.com/contact.
Related Reading
About the Author
Dr. Carlos M. Verdeza is a board certified gynecologist and the founder of G-Nouva, an integrative women’s wellness and cosmetic gynecology center in Doral, Miami. He has fifteen plus years of experience in women’s hormone care, menopause management, cosmetic gynecology, and metabolic optimization. Full bio at gnouva.com/our-authors/dr-carlos-m-verdeza.
